Long QT syndrome in adults

Area of Science:

• Cardiology
• Genetics
• Clinical Medicine

Background:

• The clinical course and risk factors for cardiac events in genotype-confirmed adult patients with long QT syndrome (LQTS) remain under-investigated.
• Understanding these factors is crucial for managing adult LQTS patients.

Purpose of the Study:

• To identify risk factors influencing the clinical course of adult patients with mutation-confirmed LQTS.
• To analyze life-threatening cardiac events as a primary endpoint in adults.
• To assess the protective efficacy of beta-blocker therapy in adult LQTS patients with known mutations.

Main Methods:

• A study involving 812 mutation-confirmed LQTS patients aged 18 years and older.
• Univariate and multivariate analyses were employed to identify genotype-phenotype factors impacting the clinical course.
• Evaluation of cardiac events and the effect of beta-blocker therapy.

Main Results:

• Female gender, corrected QT (QTc) interval, LQT2 genotype, and prior cardiac events (pre-18 years) were linked to increased cardiac event risk (18-40 years).
• Female gender, QTc interval ≥500 ms, and syncope post-18 years significantly increased the risk of life-threatening adult cardiac events.
• Beta-blockers demonstrated a 60% risk reduction for all cardiac events and life-threatening events, with greater efficacy in higher-risk individuals.

Conclusions:

• Adult LQTS severity can be stratified using genotype, gender, QTc duration, and cardiac event history.
• Beta-blockers are effective in reducing, but not fully eliminating, the risk of syncopal and life-threatening cardiac events in adult LQTS patients.